Compare JYNT & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | FATE |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.2M | 125.6M |
| IPO Year | 2014 | 2013 |
| Metric | JYNT | FATE |
|---|---|---|
| Price | $9.25 | $2.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $17.00 | $4.10 |
| AVG Volume (30 Days) | 84.9K | ★ 4.1M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.93 | 29.88 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $117,696,356.00 | $6,646,000.00 |
| Revenue This Year | $12.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $103.78 | ★ N/A |
| Revenue Growth | ★ 15.49 | N/A |
| 52 Week Low | $7.50 | $0.91 |
| 52 Week High | $12.76 | $2.88 |
| Indicator | JYNT | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 59.52 | 51.87 |
| Support Level | $8.01 | $1.01 |
| Resistance Level | $9.46 | $2.88 |
| Average True Range (ATR) | 0.44 | 0.21 |
| MACD | 0.09 | -0.04 |
| Stochastic Oscillator | 77.99 | 28.12 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.